Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report

Advanced Alzheimer’s disease is usually associated with profound and largely irreversible loss of autonomy, communication, continence, mobility, and social engagement, and care at this stage is mainly supportive. The authors note that psilocybin can alter large-scale brain network activity through 5-HT2A receptor activation and may promote plasticity in preclinical models, but clinical evidence in advanced dementia is extremely limited. Earlier human work has focused mainly on psychiatric disorders and, more recently, depression and anxiety in people with mild cognitive impairment or early Alzheimer’s disease, leaving late-stage disease poorly studied. The purpose of this report is to describe a case of transient, multidomain functional improvement in advanced Alzheimer’s disease after administration of a high dose of psilocybin-containing mushrooms. Lago and colleagues present the case as an exploratory observation intended to generate hypotheses about whether residual function in advanced neurodegeneration may be temporarily accessible under specific neuromodulatory conditions.

This paper is a single-patient case report. The patient was an octogenarian Japanese-American woman with approximately 10 years of progressive Alzheimer’s disease and about 5 years of marked functional decline, living with continuous family supervision and caregiver support. Formal biomarker confirmation and advanced neuroimaging were not available, so the diagnosis remained clinical, and the authors note that mixed or alternative neurodegenerative contributions, including vascular components, could not be fully excluded. The intervention consisted of a single oral dose of 5 g of psilocybin-containing mushrooms, identified as the Enigma strain. Because some clinically meaningful improvements persisted, a second supervised session with 3 g of psilocybin-containing mushrooms was performed one month later. The authors state that the dosing approach was exploratory, that no established psilocybin dosing framework exists for advanced dementia, and that the dose was relatively high compared with modern clinical trials. Outcomes were based on observational clinical follow-up rather than formal scales. The report tracked changes in continence, mobility, communication, emotional responsiveness, social interaction, memory-related behaviour, and acute and delayed adverse effects. No quantitative polysomnography, electrophysiology, neuroimaging, or standard cognitive testing was reported in the extracted text.

At baseline, the patient had severe hypofunction, flat affect, predominantly monosyllabic speech, reduced spontaneous interaction, urinary incontinence, impaired mobility, dysphagia, executive dysfunction, and marked dependence in daily activities. During the first session, the acute phase was marked by clinically suspected hyperthermia, profuse sweating, profound somnolence, and a prolonged deep sleep-like state, although exact temperature data were not available. About 19 h after dosing, spontaneous autobiographical conversation emerged and lasted for several hours. Over the following days and weeks, the authors report clinically meaningful improvements in multiple domains. These included restoration of urinary continence, improved ambulation, greater spontaneous communication, increased emotional responsiveness, and better contextual social interaction. The continence improvement was described as persisting for more than 5 years of prior chronic incontinence. One month later, the patient remained continent and generally improved compared with baseline. After the second supervised session with 3 g, the patient was said to show greater verbal expressivity, improved facial mimicry, spontaneous humour, emotionally positive imagery, and increased gait agility. No severe persistent adverse effects, prolonged agitation, clinically significant cardiovascular instability, persistent psychotic symptoms, delayed neurological deterioration, or delayed medical complications were observed during follow-up. The patient also spontaneously stated, “It is pleasant to come here.”

Lago and colleagues interpret the observed changes as objective improvements across autonomic, motor, executive, memory, affective, and social domains. They highlight the return of continence as especially notable because continence depends on integrated interoceptive awareness, executive inhibition, and fronto-insular network function. The authors suggest that psilocybin’s effects on large-scale brain networks, including increased global integration, cortical desynchronisation, and transient desegregation of canonical systems, could have temporarily enabled functional reintegration of residual neural systems in a person with advanced Alzheimer’s disease. They relate the unusual prolonged sleep-like state to possibly altered baseline neurophysiology in advanced Alzheimer’s disease interacting with psilocybin, while noting that earlier human studies on psilocybin and sleep have been mixed. They also place the report in the context of prior work showing psilocybin-related network reorganisation and, in some studies, improved sleep symptoms in depression. However, they stress that mechanistic interpretation remains speculative. The authors emphasise several limitations: this was a single case, there was no formal polysomnography, no quantitative electrophysiology, no neuroimaging biomarkers, and no standardised cognitive scales. They also state that causality cannot be established and that spontaneous fluctuations in neurodegenerative disease cannot be excluded. The report is presented primarily as a detailed observational description to generate hypotheses, not as evidence of reversal of Alzheimer’s pathology. The authors argue that latent functional capacity may persist in advanced neurodegeneration and may become temporarily accessible under specific neuromodulatory conditions.

The authors conclude that residual functional capacity may persist even in advanced Alzheimer’s disease and may be transiently accessed after psilocybin-induced modulation of large-scale brain networks. They state that systematic investigation is warranted.